Action required: Please refresh your browser
We have recently implemented some changes that require a hard refresh of your browser: Please hold down the CTRL-key and press the F5 key.
After a successful hard refresh, this message should not appear anymore.
More details about this topic are available here »
RepliCel Presenting at InvestMNT Investor Conference in Minneapolis | ||
By: PR Newswire Association LLC. - 03 Aug 2015 | Back to overview list |
|
Conference attracts investment professionals in the Twin Cities area VANCOUVER, BC, Aug. 3, 2015 /CNW/ - RepliCel Life Sciences Inc. (TSX.V: RP) (OTCQB: REPCF), a clinical stage regenerative medicine company focused on the development of autologous cell therapies, announced today that RepliCel's CEO, David Hall, will be presenting at the InvestMNT conference held in Minneapolis, Minnesota on August 5th at 8:15 AM local time. Hall's presentation will highlight RepliCel's 18-month milestones including CE Mark for its RCI-02 dermal injector for sale in Europe, clinical data from both RCT-01 (tendon) and RCS-01 (skin) clinical trials in Canada and Germany, as well as Shiseido's proposed pattern baldness clinical trial in Japan using RepliCel's RCH-01 (hair) product. The conference is hosted by the CFA Society of Minnesota and will take place at the Schulze School of Entrepreneurship, University of St. Thomas, Minneapolis Campus, 1000 LaSalle Avenue, Minneapolis. To learn more about the conference or if you're interested in attending, click here. About InvestMNT About RepliCel For more information please contact: INVESTOR RELATIONS: Neither TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release. SOURCE RepliCel Life Sciences Inc. |
||
|
||
Copyright 2015 PR Newswire Association LLC. | Back to overview list |